Table 3

Most frequently reported adverse events in the two treatment groups summarised by body system

Sulphasalazine (n=37) Placebo (n=42)
Gastrointestinal disorders1310
CNS disorders97
Skin disorders44
Leucopenia21
Total number of adverse events3930
Total number of patients with adverse events2219